Determination of anandamide and other fatty acyl ethanolamides in human serum by electrospray tandem mass spectrometry

Analytical Biochemistry

Volumn 361, Issue 2, 2007, Pages 162-168

  Schreiber, Daniela ^a   Harlfinger, Stephanie ^a   Nolden, Brit M ^a   Gerth, Christoph W ^a   Jaehde, Ulrich ^b   Schömig, Edgar ^a   Klosterkötter, Joachim ^a   Giuffrida, Andrea ^c   Astarita, Giuseppe ^d   Piomelli, Daniele ^d   Markus Leweke, F ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anandamide; Fatty acid ethanolamides; Human; Liquid chromatography; Tandem mass spectrometry

Indexed keywords

ELECTROSPRAY IONIZATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY;

ANANDAMIDE; CALIBRATION CURVES; CANNABINOID RECEPTORS; ELECTROSPRAY TANDEM MASS SPECTROMETRY; HUMAN; QUANTIFICATION LIMIT; SELECTIVE LIQUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY;

FATTY ACIDS;

ANANDAMIDE; CANNABINOID RECEPTOR; N OLEOYLETHANOLAMINE; PALMIDROL;

ANALYTIC METHOD; ARTICLE; CALIBRATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SERUM; TANDEM MASS SPECTROMETRY;

EID: 33846365939     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2006.11.027     Document Type: Article

References (32)

1. Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 4 (2003) 873-884
2. Mackie K. Mechanisms of CB1 receptor signaling: endocannabinoid modulation of synaptic strength. Int. J. Obes. (Lond). 30 Suppl. 1 (2006) S19-S23
3. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
4. Munro S., Thomas K.L., and Abu Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
5. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., and Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372 (1994) 686-691
6. Cadas H., Gaillet S., Beltramo M., Venance L., and Piomelli D. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J. Neurosci. 16 (1996) 3934-3942
7. Cadas H., Di Tomaso E., and Piomelli D. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J. Neurosci. 17 (1997) 1226-1242
8. Perlik F., Raskova H., and Elis J. Anti-inflammatory properties of N(2-hydroxyethyl) palmitamide. Acta Physiol. Acad. Sci. Hung. 39 (1971) 395-400
9. Mazzari S., Canella R., Petrelli L., Marcolongo G., and Leon A. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur. J. Pharmacol. 300 (1996) 227-236
10. Calignano A., La Rana G., Giuffrida A., and Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 394 (1998) 277-281
11. Rodriguez De Fonseca F., Navarro M., Gomez R., Escuredo L., Nava F., Fu J., Murillo-Rodriguez E., Giuffrida A., LoVerme J., Gaetani S., Kathuria S., Gall C., and Piomelli D. An anorexic lipid mediator regulated by feeding. Nature 414 (2001) 209-212
12. Fu J., Oveisi F., Gaetani S., Lin E., and Piomelli D. Oleoylethanolamide, an endogenous PPAR-[alpha] agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology 48 (2005) 1147-1153
13. Giuffrida A., Leweke F.M., Gerth C.W., Schreiber D., Koethe D., Faulhaber J., Klosterkötter J., and Piomelli D. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29 (2004) 2108-2114
14. Leweke F.M., Giuffrida A., Wurster U., Emrich H.M., and Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuro. Report 10 (1999) 1665-1669
15. Fegley D., Gaetani S., Duranti A., Tontini A., Mor M., Tarzia G., and Piomelli D. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J. Pharmacol. Exp. Ther. 313 (2005) 352-358
16. Giuffrida A., Rodriguez de Fonseca F., and Piomelli D. Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry. Anal. Biochem. 280 (2000) 87-93
17. Koga D., Santa T., Fukushima T., Homma H., and Imai K. Liquid chromatographic-atmospheric pressure chemical ionization mass spectrometric determination of anandamide and its analogs in rat brain and peripheral tissues. J. Chromatogr. B. Biomed. Sci. Appl. 690 (1997) 7-13
18. Winstein S. The coordination of silver ion with unsaturated compounds. J. Am. Chem. Soc. 60 (1938) 836
19. Nichols P.L. Coordination of silver ion with methyl esters of oleic and elaidic acids. J. Am. Chem. Soc. 74 (1952) 1091-1093
20. Morris L.J. Separations of lipids by silver ion chromatography. J. Lipid Res. 7 (1966) 717-732
21. + coordination tandem mass spectrometry. Anal. Biochem. 314 (2003) 8-15
22. Giuffrida A., and Piomelli D. Purification and high-resolution analysis of anandamide and other fatty acylethanolamides. In: Laychock S.G., and Rubin R.P. (Eds). Lipid Second Messengers (1998), CRC Press, Boca Raton; London; New York; Washington, D.C. 113-133
23. Shah V.P., Midha K.K., Findlay J.W., Hill H.M., Hulse J.D., McGilveray I.J., McKay G., Miller K.J., Patnaik R.N., Powell M.L., Tonelli A., Viswanathan C.T., and Yacobi A. Bioanalytical method validation-a revisit with a decade of progress. Pharm. Res. 17 (2000) 1551-1557
24. CPMP/ICH/281/95, EEC Note for Guidance, Validation of Analytical Procedures: Methodology, London, 1996.
25. CPMP/ICH/381/95, EEC Note for Guidance, Validation of Analytical Procedures: Definitions and Terminology, London, 1994.
26. FDA Food and Drug Administration, Guidance for Industry: Bioanalytical Method Validation, 2001.
27. De Marchi N., De Petrocellis L., Orlando P., Daniele F., Fezza F., and Di Marzo V. Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis. 2 (2003) 5-13
28. Bisogno T., Maurelli S., Melck D., De Petrocellis L., and Di Marzo V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem. 272 (1997) 3315-3323
29. Schmid P.C., Kuwae T., Krebsbach R.J., and Schmid H.H. Anandamide and other N-acylethanolamines in mouse peritoneal macrophages. Chem. Phys. Lipids 87 (1997) 103-110
30. Kuwae T., Shiota Y., Schmid P.C., Krebsbach R., and Schmid H.H. Biosynthesis and turnover of anandamide and other N-acylethanolamines in peritoneal macrophages. FEBS Lett. 459 (1999) 123-127
31. Maccarrone M., Bari M., Battista N., and Finazzi-Agro A. Endocannabinoid degradation, endotoxic shock and inflammation. Curr. Drug Targets Inflamm. Allergy 1 (2002) 53-63
32. Re G., Barbero R., Miolo A., and Di Marzo V. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet. J. (2005) (Epub ahead of print).